79 related articles for article (PubMed ID: 23806057)
1. The effect of hepatitis C treatment response on medical costs: a longitudinal analysis in an integrated care setting.
Manos MM; Darbinian J; Rubin J; Ray GT; Shvachko V; Denis B; Velez F; Quesenberry C
J Manag Care Pharm; 2013; 19(6):438-47. PubMed ID: 23806057
[TBL] [Abstract][Full Text] [Related]
2. Estimation of direct medical cost related to the management of chronic hepatitis C and its complications in South Korea.
Kim DY; Yoon KT; Kim W; Lee JI; Hong SH; Lee D; Jang JW; Choi JW; Kim I; Paik YH
Medicine (Baltimore); 2016 Jul; 95(30):e3896. PubMed ID: 27472670
[TBL] [Abstract][Full Text] [Related]
3. Does Hepatitis C Treatment Adherence Affect Risk of Liver Transplantation? A Historical Cohort Study.
Ems D; Racsa P; Anderson C; Gregory F; Worley K; Brill JV; Holt W
J Manag Care Spec Pharm; 2016 Jul; 22(7):863-71. PubMed ID: 27348286
[TBL] [Abstract][Full Text] [Related]
4. Outcomes and Costs of Treating Hepatitis C Patients in the Era of First Generation Protease Inhibitors - Results from the PAN Study.
Stahmeyer JT; Rossol S; Bert F; Böker KH; Bruch HR; Eisenbach C; Link R; John C; Mauss S; Heyne R; Schott E; Pfeiffer-Vornkahl H; Hüppe D; Krauth C
PLoS One; 2016; 11(7):e0159976. PubMed ID: 27467772
[TBL] [Abstract][Full Text] [Related]
5. Assessing the validity of a data driven segmentation approach: A 4 year longitudinal study of healthcare utilization and mortality.
Low LL; Yan S; Kwan YH; Tan CS; Thumboo J
PLoS One; 2018; 13(4):e0195243. PubMed ID: 29621280
[TBL] [Abstract][Full Text] [Related]
6. Estimation of average diagnosis and treatment costs of hepatitis C.
Ashtari S; Vahedi M; Pourhoseingholi MA; Pourhoseingholi A; Safaee A; Moghimi-Dehkordi B; Zali MR
Gastroenterol Hepatol Bed Bench; 2012; 5(3):139-45. PubMed ID: 24834215
[TBL] [Abstract][Full Text] [Related]
7. Liver Impairment and Hematological Changes in Patients with Chronic Hepatitis C and COVID-19: A Retrospective Study after One Year of Pandemic.
Cerbu B; Pantea S; Bratosin F; Vidican I; Turaiche M; Frent S; Borsi E; Marincu I
Medicina (Kaunas); 2021 Jun; 57(6):. PubMed ID: 34200570
[No Abstract] [Full Text] [Related]
8. No Patient Left Behind: A Novel Paradigm to Fulfill Hepatitis C Virus Treatment for Rural Patients.
Gormley MA; Moschella P; Cordero-Romero S; Wampler WR; Allison M; Kitzmiller K; Estes L; Heo M; Litwin AH; Roth P
Open Forum Infect Dis; 2024 May; 11(5):ofae206. PubMed ID: 38737428
[TBL] [Abstract][Full Text] [Related]
9. Hepatology outpatient service provision in secondary care: a study of liver disease incidence and resource costs.
Whalley S; Puvanachandra P; Desai A; Kennedy H
Clin Med (Lond); 2007 Apr; 7(2):119-24. PubMed ID: 17491498
[TBL] [Abstract][Full Text] [Related]
10. Accounting for the Discrepancies in Treatment Completion and SVR in OPPORTUNI-C.
El-Dalati S; Stoner BJ
Clin Infect Dis; 2024 Jun; ():. PubMed ID: 38824444
[No Abstract] [Full Text] [Related]
11. Cost-effectiveness of novel regimens for the treatment of hepatitis C virus.
Najafzadeh M; Andersson K; Shrank WH; Krumme AA; Matlin OS; Brennan T; Avorn J; Choudhry NK
Ann Intern Med; 2015 Mar; 162(6):407-19. PubMed ID: 25775313
[TBL] [Abstract][Full Text] [Related]
12. Impact of completing chronic hepatitis C (CHC) treatment on post-therapy healthcare cost.
Tandon N; Balart LA; Laliberté F; Pilon D; Lefebvre P; Germain G; Prabhakar A
J Med Econ; 2014 Dec; 17(12):862-71. PubMed ID: 25215925
[TBL] [Abstract][Full Text] [Related]
13. The changing epidemiology of hepatitis C virus infection in the United States: National Health and Nutrition Examination Survey 2001 through 2010.
Ditah I; Ditah F; Devaki P; Ewelukwa O; Ditah C; Njei B; Luma HN; Charlton M
J Hepatol; 2014 Apr; 60(4):691-8. PubMed ID: 24291324
[TBL] [Abstract][Full Text] [Related]
14. Cost analysis of sofosbuvir/ribavirin versus sofosbuvir/simeprevir for genotype 1 hepatitis C virus in interferon-ineligible/intolerant individuals.
Hagan LM; Sulkowski MS; Schinazi RF
Hepatology; 2014 Jul; 60(1):37-45. PubMed ID: 24677184
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States.
Chhatwal J; Kanwal F; Roberts MS; Dunn MA
Ann Intern Med; 2015 Mar; 162(6):397-406. PubMed ID: 25775312
[TBL] [Abstract][Full Text] [Related]
16. Sofosbuvir-based treatment regimens for chronic, genotype 1 hepatitis C virus infection in U.S. incarcerated populations: a cost-effectiveness analysis.
Liu S; Watcha D; Holodniy M; Goldhaber-Fiebert JD
Ann Intern Med; 2014 Oct; 161(8):546-53. PubMed ID: 25329202
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness analysis of sofosbuvir-based regimens for chronic hepatitis C.
San Miguel R; Gimeno-Ballester V; Blázquez A; Mar J
Gut; 2015 Aug; 64(8):1277-88. PubMed ID: 25311032
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness of sofosbuvir in the treatment of patients with hepatitis C.
Leleu H; Blachier M; Rosa I
J Viral Hepat; 2015 Apr; 22(4):376-83. PubMed ID: 25219291
[TBL] [Abstract][Full Text] [Related]
19. Impact of interferon free regimens on clinical and cost outcomes for chronic hepatitis C genotype 1 patients.
Younossi ZM; Singer ME; Mir HM; Henry L; Hunt S
J Hepatol; 2014 Mar; 60(3):530-7. PubMed ID: 24269472
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness analysis of sofosbuvir plus peginterferon/ribavirin in the treatment of chronic hepatitis C virus genotype 1 infection.
Saab S; Gordon SC; Park H; Sulkowski M; Ahmed A; Younossi Z
Aliment Pharmacol Ther; 2014 Sep; 40(6):657-75. PubMed ID: 25065960
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
